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Abstract: The medical treatment of glaucoma has evolved significantly over the past several 
decades. The main driving forces behind this evolution are the safety profiles and efficacy of 
these medications. Prostaglandin (PG) analogues are shown to be superior to older drugs in both 
efficacy and tolerability. Though there are much fewer side effects that manifest after using PG 
analogues, the adherence and compliance to medication regimens are surprisingly lower than 
expected. A commonly sited reason is the ocular irritation and inflammation with these medica-
tions. Much of this inflammation can be attributed to the preservative, benzalkonium chloride 
(BAK). The chronic clinical and subclinical inflammation becomes increasingly detrimental 
when filtration surgery fails from bleb fibrosis secondary to this hypercellularity. A BAK-free 
formulation of a PG analogues recently became available. BAK-free travoprost is reviewed here. 
It has demonstrated equal efficacy and less ocular surface toxicity than its preserved counterparts. 
It is expected to serve as an instrumental resource in managing ocular hypertension and glau-
coma in patients who demonstrate significant sensitivity to BAK. More randomized, controlled, 
double-blind studies are encouraged to evaluate its improved safety and tolerability.
Keywords: glaucoma, benzalkonium chloride, Travatan Z, sofZia
Introduction
This is a literature review, which discusses medical therapy of glaucoma and focuses on 
adverse effects of the topical drugs. An overview of the prevalence of glaucoma, anti-
glaucoma medications, their side effects, and consequences of these side effects is pro-
vided, with particular emphasis on prostaglandin (PG) analogues.   Preservative-induced 
ocular irritation and the interaction of PGs with benzalkonium chloride (BAK) are 
addressed. The subsequent development of preservative-free glaucoma medications and 
their efficacy and safety profile are then examined. Newly available travoprost preserved 
with sofZia™ (Alcon Laboratories, Inc, Fort Worth, Texas, USA) is described, and the 
research evaluating the efficacy and safety profile of this drug is reviewed.
Epidemiology
Worldwide, approximately 60.5 million people have glaucoma, based on a literature 
search of over 2,000 studies. Open-angle glaucoma and angle-closure glaucoma were 
measured by optic disc changes, and visual field test abnormalities did not account 
for intraocular pressure (IOP); 79.6 million people are expected to have glaucoma 
by 2020. Glaucoma is a leading cause of blindness, second only to cataracts. Data 
indicate that there is a propensity for Asians and females to develop   glaucoma.1 
There is a large body of literature that analyzes prevalence data globally, and despite Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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variations in extrapolating numbers from studies and test-
ing measures, there is no doubt glaucoma is an increasingly 
common pathology.2,3 Recent reports from the World Health 
Organization indicate that of the 37 million people who are 
currently blind, 4.5–5 million are blind due to glaucoma.4 
Prevalence rates also increase as the population grows older. 
Of persons older than 40 years, 2.4% have glaucoma, and this 
increases to 7% among those older than 70.5 In the United 
States alone, the prevalence of glaucoma in individuals 
40 years or older is 2.2 million and is estimated to increase 
to 3.6 million by 2020 due to the rapidly aging population. 
There is a significant difference in prevalence rates based on 
race; African American individuals are 3 times more likely 
to have glaucoma than Caucasian individuals.6 Among indi-
viduals of Caucasian decent who are 73 and 74 years old, 
the prevalence of glaucoma was shown to be 3.4%; the rate 
increased to 9.5% among Caucasians who were older than 
73 or 74 years. Among participants of African American 
ethnicity, rates were 5.7% for those who were 73 and 74 and 
increased to 23.2% among those older than 75.7 It is also 
estimated that this disease process costs the US health care 
system $2.5 billion, and individuals undergoing treatment 
spend between US $600 and US $2,500 per person annually, 
indicating a significant burden on the population.8 Based 
on the copious epidemiologic data available, it is expected 
that glaucoma will be among the leading diseases treated by 
ophthalmologists worldwide.
Use of medications for glaucoma
Among clinicians, it is well understood that medical therapy 
for open-angle glaucoma is most often the initial therapy 
for newly diagnosed patients and will continue to be used, 
often for decades, as long-term management. The Ocular 
Hypertension Treatment study demonstrated the efficacy of 
medications as they significantly reduced the rate of devel-
oping glaucoma among those with elevated IOP; 9.5% of 
untreated participants and only 4% of treated subjects devel-
oped glaucoma. This risk factor is especially pronounced 
among African Americans who participated in the trial.9 
Reducing IOPs is shown to be imperative to slow disease 
progression for those with open-angle glaucoma, normal-
tension glaucoma, or just ocular hypertension.10 For several 
reasons, including easier accessibility compared with surgery 
and often similar outcomes regarding IOP of surgery and 
medication, medications remain the first line of therapy.11 
Among these medications, PG analogues exhibit several 
advantages over other medical therapies. This class of drugs 
is able to decrease IOPs by up to 33%, which is a greater 
decrease than other classes reviewed, including β-blockers, 
α2 adrenergics, and carbonic anhydrase inhibitors.12 There 
is a higher rate of adherence to treatment regimens as these 
drugs require only once-a-day dosing. The pressure-lowering 
effects can last up to 2 days and have a short half-life, which 
reduces the systemic side effect profile. The mechanism of 
action for the 3 major PG analogues or prostamides available 
is an increase in both trabecular and uveoscleral outflow, as 
they may work through a pressure-sensitive and/or pressure-
insensitive pathway.13 Two of the PG analogues are prepared 
as prodrug isopropyl esters, which assist in accessing the 
cornea so that they can undergo hydrolyzation by esterase, 
which in turn allows them to enter the aqueous humor. There 
is minimal to no difference in the pressure-lowering effects 
of latanoprost and travoprost long term, and travoprost may 
maintain lower pressures in the late afternoon as compared 
with latanoprost. Ocular hyperemia was associated more 
with travoprost, though this was not significant.14 As the 
importance of medical therapy is quite established in clini-
cal practice and medications are shown to be efficacious, 
the concern of medication safety remains uncertain. Dry eye 
is more prevalent among those with glaucoma than in the 
general population.15
Dry eye in the general population
Population-based studies, which look at the pervasiveness 
of dry eye disease (DED), found that DED is a common 
problem among several sectors of the population including 
postmenopausal women and the elderly. Several studies 
conducted in the United States indicate that the prevalence 
of dry eye among individuals of an approximate age of 50 or 
older is from 7% to 33%.16–18 The prevalence of dry eye and 
dry mouth (sicca syndrome) was reported to be 27% among 
the elderly. In one study of 2,481 individuals between the 
ages of 65 and 84, there was a positive and dose-response 
association between dry eye or dry mouth and the use of 
certain medications, which could cause ocular irritation 
through several different mechanisms. To what extent 
could the signs and symptoms of dry eye be attributed to 
medications may not be entirely clear; however, a signifi-
cant percentage of the population (62%) had dry eye or dry 
mouth symptoms associated with medication usage.19 The 
international prevalence of dry eye syndrome, including 
studies conducted in Canada, Taiwan, Indonesia, Australia, 
and Japan, is similar to rates seen in the United States.18,20–23 
The reduction of quality of life and mounting costs of DED 
is quite significant. One study used utility assessment scores 
to compare the quality of life of those with DED and other Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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common pathologies. The utility scores for dry eye correlated 
remarkably with scores for several systemic pathologies. 
Mild dry eye had utility scores comparable with psoriasis, 
scores for moderate dry eye were comparable with those for 
moderate angina, whereas severe dry eye scoring was com-
parable with utility scores for hip fractures.24 The costs of 
this debilitating condition are reflected in the large number 
of individuals who spend each year on lubricating solutions. 
In a 6-country study, the prevalence of individuals who see 
their ophthalmologist for dry eye was approximated at 0.1%, 
and the yearly costs of 1,000 patients who were being treated 
by their ophthalmologists ranged from US$0.27 million in 
France to US$1.10 million in the United Kingdom.25 These 
expenses only reflect the amount being spent by individuals 
who have their ophthalmologist manage their symptoms; they 
do not reflect the likely million more people who suffer from 
dry eye and spend money self medicating.
Dry eye associated with glaucoma 
medications
Clinicians who manage glaucoma are well aware of the 
associated ocular surface disease (OSD) and inflammation 
associated with glaucoma medication. The prevalence of 
dry eye among these individuals is delineated in several 
surveys and cross-sectional studies. Although there are sev-
eral studies, the diagnosis of DED is highly variable due to 
the flexible definitions of dry eye.26 One analysis used the 
Medical Expenditure Panel Survey, a national health survey, 
and examined the rates of dry eye, identified by diagnosis or 
the use of prescribed medications for dry eye. The rate of dry 
eye syndrome was compared between those with glaucoma, 
identified by the use of glaucoma medication, and nonglau-
coma controls. Patients with dry eye were more commonly 
females and had higher rates of diabetes and hypertension. 
Respondents with glaucoma demonstrated dry eye 16.5% 
of the time, whereas nonglaucoma controls were associated 
with dry eye only 5.6% of the time. Importantly, among the 
glaucoma patients, those using adjunctive therapy reported 
higher rates of dry eye than those who did not; however, 
these data are not significant, possibly due to a lower power 
in the study.
PG analogues were the most commonly prescribed 
medication for those with and without dry eye. There was a 
higher ratio of people who had both dry eye and glaucoma 
(21%) than those who had only dry eye(7.4%), which is 
  compelling data that support the concern of glaucoma 
medication-induced DED. This is more substantial when 
considering this study only in those with dry eye clinically 
significant enough to warrant medication, leaving out all 
subclinical cases.27 Other studies show that the severity of 
dry eye among glaucoma patients increases with the   number 
of antiglaucoma medications being used.28,29 Patients using 
glaucoma medications for at least 6 months or longer dem-
onstrated a significantly larger amount of inflammatory 
markers on the ocular as measured via antibodies to several 
cytokines. In this study, there was no significant difference 
in the amount of cytokines found in those who used more 
than 1 glaucoma medication.30
Costs of hyperemia induced 
by PG analogues
When researchers calculated the costs of switching from 1 PG 
analogues, bimatoprost, latanoprost, or travoprost, to 1 of 
the other 2 PG analogues based on physician-recommended 
  medication switches due to hyperemia, there was a notable dif-
ference. The costs were calculated from the amount charged for 
the office visit and the amount of the new   prescription. Costs 
for hyperemia-free patients were US$73.67, and costs for 
those whose medications were changed due to hyperemia were   
US$140.02. Costs were lowest for patients who started the 
study with latanoprost, indicating their medications were 
switched less often; costs were highest for travoprost, which 
were only 50 cents higher than for bimatoprost.31 These 
increased costs indicate that conjunctival hyperemia, which 
is clinically significant enough to switch medications, is 
expensive for patients and time consuming for physicians.
Compliance or adherence
Besides the costs of medication-induced OSD, patient-
  reported ocular irritation and/or inflammation is, as 
described, common and should be considered an even greater 
factor when prescribing medications for   glaucoma.32 One 
of the most common side effects attributed to this class of 
drugs is hyperemia, which has been found in nearly two-
thirds of patients experiencing adverse effects.33 Clinicians 
often report that this prevalent and seemingly benign side 
effect can be quite deleterious. Because hyperemia, among 
other side effects, is not aesthetically pleasing to patients, 
they are often nonadherent to their dosing schedule, leading 
to uncontrolled pressures and further disease progression.34 
Several investigations of glaucoma medication adherence 
were performed. One cross-sectional study completed in 
Australia conducted surveys inquiring patients’   compliance 
with medication regimens. Of the participants, 45% reported 
nonadherence, in which 66% were unintentional nonadher-
ence and 17% reported either intentionally missing doses Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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or both. Those who forgot doses were generally younger, 
had less comorbidities, and tended to report not believing 
in medication efficacy for glaucoma. Intentionally missing 
doses were associated with concerns about medications.35 
A reviewer searched literature from 1980 to 2004 regard-
ing patients’ adherence and duration of continuation of 
utilization of ocular hypotensives. Several methods of 
measurement of adherence and persistence were encoun-
tered; noncompliance rates of 25% or more were frequently 
reported. Also reported was that nonadherence was attrib-
uted to situational/environmental reasons or side effects/
complexity of regimens of medications. In addition, the 
reviewer reported that less than 25% of patients were 
persistent over 12 months.36 Other factors that cause this 
characteristic adherence pattern to glaucoma medications are 
described in a part retrospective and part prospective study, 
which elucidates several variables including patients’ educa-
tion of glaucoma, patients’ beliefs in medication efficacy, 
payment for medications, situational or traveling, and not 
acknowledging side effects. In their conclusion, they found 
that focusing on patients’ education was associated with 
better adherence to medication regimens.33
Hyperemia attributed  
to preservatives
Ocular irritation and scleral injection associated with PG 
analogues have been attributed to preservatives in ophthal-
mic solutions. Parrish et al37 showed that after over 3 weeks 
of treatment, subjects who reported mild hyperemia were 
associated with the usage of bimatoprost 69% of the time, 
with travoprost 58% of the time, and with latanoprost 
47% of the time. Moderate hyperemia was also reported 
to be associated with bimatoprost 15% of the time, with 
travoprost 10% of the time, and with latanoprost 6% of the 
time. There is much subjective and objective evidence that 
indicates preserved medications cause significant ocular 
disease.38 Some investigators distributed a survey question-
naire to patients using either preserved or preservative-free 
glaucoma medications for a long term and found that symp-
toms such as foreign body sensation, stinging, burning, and 
tearing were associated more with those using preserved 
medications. Moreover, when patients were switched to 
preservative-free formulations, their symptoms decreased 
or disappeared.39,40
Though preservatives are associated with a spectrum of 
symptomatic irritation, they are necessary to maintain steril-
ity of multiuse ophthalmic solutions, without which they are 
more likely to be contaminated.41 In unpreserved   ophthalmic 
preparations, contamination usually occurs within 1–2 weeks 
of twice-daily usage.42 Other studies demonstrated con-
tamination in almost 20% of unpreserved solutions less than 
8 weeks old and 40% contamination in those greater than 
8 weeks old.43 BAK, a common preservative, is a quaternary 
ammonium compound. It is used in approximately 70% of 
preserved ophthalmic solutions and only 10% use other 
preservatives.44 It is an extremely capable preservative in 
regards to its microbial coverage and its capacity to break 
cell–cell junctions on the corneal epithelium, thus allowing 
entry into the anterior chamber.45–47 BAK as a polyquaternary 
ammonium compound acts as a detergent, which lyses cell 
membranes.48 Moreover, it remains in the eye long after its 
application as it incorporates itself into cell membranes for 
up to 7 days and has a half-life of 12 hours.49–51 Standard 
concentrations range from 0.015% to 0.02% BAK in oph-
thalmic solutions; however, toxicity has been demonstrated 
at concentrations as low as 0.005% BAK.52 There is, thus, 
reason to believe that such preservatives accumulate on the 
ocular surface as they are used at least once daily. As the 
preservative is collected on the ocular surface, prolonged 
exposure leads to toxicity.53 There are a slew of studies that 
investigate the effects of this preservative on the ocular sur-
face. In vitro studies demonstrate the necrotic and apoptotic 
effects.54 Other studies show cell fragmentation, fibroblast 
proliferation, cell shrinkage, and cell death when tissue 
cultures are exposed to preservative alone and medications 
preserved with BAK.55 Antiglaucoma drops preserved with 
BAK are also strongly associated with topical   inflammation.56 
Several in vitro studies demonstrate a notable amount of 
toxicity to cells from the Chang and Wong-Kilbourne 
human conjunctival cell line, which are exposed to BAK, 
even at extremely low concentrations.57,58 When comparing 
the cytological differences of the conjunctiva of individuals 
using glaucoma medications and those who do not, there 
is a marked contrast. Those who have used antiglaucoma 
medications for even a short amount of time (14 days) 
display reduction in the number of goblet cells, epithelial 
keratinization, and squamous metaplasia.59,60 PGs have been 
especially scrutinized. Though they have a low systemic side 
effect profile, they are, as discussed earlier, infamous for the 
injection and inflammation with which they are associated, 
leading to poor adherence.
PG analogues preserved with BAK
Compared with other classes of antiglaucoma drugs, 
PG analogues have typically demonstrated less systemic 
side effects. Among the different formulations of PG Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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analogues, the ocular side effect profiles are variable. 
One of the more commonly reported adverse effects 
is ocular hyperemia.34 To evaluate the association of 
these drugs and the widely reported ocular hyperemia, 
Guenoun et al61 evaluated the role of 3 PG analogues 
on the expression of inflammatory markers using flow 
cytometry on a human conjunctival cell line. The results 
were compared with 3 controls including PGF2α, tumor 
necrosis factor α (TNFα), and BAK at the 3 concentra-
tions found in the commercial preparations of the PG 
analogues. PGF2α did not demonstrate any induction 
effect. As predicted, TNFα induced all inflammatory 
markers at significantly higher levels than controls and 
BAK. BAK decreased the expression of the 2 adhesion 
molecules, likely due to the cytotoxicity as evidenced by 
DNA condensation evaluated by fluorocytometry.61 This 
is consistent with the widely known, dose-dependent 
deleterious cellular effects of BAK.57 The PG analogues 
also decreased the expression of inflammatory markers 
with latanoprost inducing the least amount of expression, 
followed by travoprost and then bimatoprost. Interest-
ingly, the amount of inflammatory markers’ expression 
negatively correlated with the concentration of BAK 
in each formulation. In other words, latanoprost has 
a higher concentration of BAK, but induced the least 
amount of inflammatory markers, which could be possi-
bly due to the more immediate cytotoxicity than inflam-
mation. Also, when this group evaluated for apoptosis, 
it was found that cell death also demonstrated a positive 
correlation with the concentrations of BAK in the 3 PG 
analogues. This led to the conclusion that BAK was 
responsible for the inflammation and cellular toxicity 
that were associated with PG analogues. This may also 
explain the paradoxical reduction in ocular hyperemia 
seen with latanoprost compared with travoprost and 
bimatoprost. Compared with the trials of isolated BAK 
at concentrations found in commercial formulations, 
there was slightly more cell death and inflammation 
with BAK alone than with the commercial preparations, 
suggesting that the PG analogues have a protective role 
against the harmful effects of BAK.61 The role of PG 
cytoprotection was also introduced by a study, which 
compared latanoprost with β-blockers and BAK alone 
at concentrations found in the preserved preparations. 
Latanoprost again demonstrated less toxicity than the 
preserved β-blockers and solitary BAK at the same con-
centration, further suggesting a defensive role against 
preservative-induced damage.58
Possible PG analogue 
cytoprotection from BAK
In order to further investigate the cytoprotective mechanisms 
of PG analogues against BAK toxicity that were previously 
demonstrated, trials comparing the 3 leading PG analogues 
were completed. Using Chang cells and exposing them to 
the same PG analogues and similar concentrations of soli-
tary BAK for 30 min, this group measured cell membrane 
compromise, cytosolic H2O2, cytosolic O2 free radicals, 
and apoptosis. As expected, solitary BAK demonstrated a 
dose-dependent effect. Latanoprost and travoprost were less 
detrimental than the corresponding BAK concentration. Both 
had significantly reduced amounts of H2O2 and proapoptotic 
effects, and latanoprost created less O2 radicals than the BAK 
counterpart. Bimatoprost did not, however, demonstrate this 
protective effect but demonstrated the least apoptotic effect as 
it had the lowest concentration of BAK among the 3. Based 
on this study, it appears that BAK causes oxidative effects 
that incite cytotoxicity, which is dose dependent. Although 
it appears that these PGF2α analogues are antioxidative, 
PGFs are widely known to be proinflammatory.61,58   Perhaps 
the PGF analogues reduce the amount of generation of 
reactive oxygen species or induce other mechanisms of 
antioxidation or antiapoptosis; hence, this possibility could 
be further investigated. Another prospective explanation 
cited by the authors included the potential for BAK and the 
PG analogues forming an emulsion, thus reducing the BAK 
exposure. Though the mechanism for PG cytoprotection is 
not fully elucidated, the concept of PGF-related buffering of 
  BAK-induced toxicity may have implications for its use.62
Despite the complexities of the interaction of BAK and 
PG analogues and the mechanism of medication-induced 
hyperemia and irritation, medications and their preservatives 
play a role in the development of OSD.38
Consequences of chronic 
inflammation on surgical outcomes
One of the most concerning effects of the subclinical inflam-
mation caused by glaucoma medications is the failure of fil-
tration surgery, which is often a last resort in the treatment of 
glaucoma.63,64 Success rates for trabeculectomy were almost 
2 times greater for patients who used minimal glaucoma 
medications compared with those who used at least 2 medi-
cations. In addition, preoperative hypercellularity of chronic 
inflammatory cells (including fibroblasts, macrophages, 
and lymphocytes) of the trabecular meshwork was much 
lower for those who had successful surgeries in contrast to Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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those whose surgeries failed. The presence of inflammatory 
cells may cause fibrosis of the bleb. Such data indicate a 
strong positive correlation between glaucoma medication 
and surgery failure.65 Several studies support the argument 
that filtration surgery is affected by the duration of use and 
the number of glaucoma medications being used by the 
patients.66–70 Preservative toxicity, specifically BAK toxicity, 
is suggested as a clear suspect in inducing this chronic and 
mild inflammatory response, which is strongly associated 
with detrimental surgery outcomes.71 Some investigators 
have suggested that there may be a trend toward alternative 
preservatives or preservative-free formulations in medical 
glaucoma treatment.66,72
Options for alternative 
preservatives
An interesting alternative option for preservatives is emul-
sions. Oil-in-water emulsions were developed several years 
ago as a possible alternative for treating dry eye associated 
with ophthalmic solutions. By positively charging the mol-
ecules using quaternary ammonium compounds, these emul-
sion solutions are attracted to the negatively charged ocular 
surface.73 This interaction provides increased amounts of 
time for the emulsion to remain on the ocular surface. BAK 
is comprised of several ammonium chlorides with differ-
ent alkyl chain lengths. As both a preservative with toxic 
effects and a quaternary ammonium compound, which is 
positively charged, its excellent antimicrobial effectiveness is 
marred by its detrimental damage to the cells. BAK remains 
mostly in the lipophilic phase when prepared as an emulsion 
solution.74 Only 1.2% of BAK is the free and actively toxic 
preservative.75 Studies have shown that emulsions of BAK 
preservative reduce its detrimental effects, but they do not 
eliminate them.76
Although there are several other preservatives available, 
including phenylmercuric nitrate, chlorhexidine acetate, 
chlorobutanol, and polyquaternium-1, they have several dis-
advantages, including insufficient microbial coverage, being 
easily rendered inactive by common organic compounds or 
room temperatures, or causing similar detrimental effects 
of BAK on the ocular surface. Certain antimicrobials such 
as sorbate, which has almost no side effect profile, sodium 
perborate, which has a minimal side effect profile and very 
good microbial coverage, and stabilized oxychloro complex 
(SOC), which also provides broad spectrum of protection 
while being gentle, are other alternatives to BAK. SOC is 
an oxidant preservative, as opposed to detergent preserva-
tives, is also known to disrupt cellular membranes, but only 
mildly. The selective bacteriocidal and fungicidal activities of 
oxidant preservatives are derived from their inherent ability 
to create oxidative stress, which eukaryotic cells are able to 
withstand through their antioxidant and enzymatic neutral-
izing agents.77 SOC is currently available as a preservative 
for 0.1% brimonidine tartrate (Alphagan® P; Allergan, Irvine, 
California, USA), but the IOP-lowering capability is not as 
great as other medications. A newer preservative, sofZia is 
being used in preparations of travoprost. It is an ionic, buff-
ered formula composed of zinc, borate, propylene glycol, 
and sorbitol. SofZia is effective in microbicidal activity for 
up to 99% of microorganisms after an 8-day incubation, 
and it meets the antimicrobial criteria of the United States 
Pharmacopeia.78
Efficacy and comfort  
of preservative-free non-PG  
ocular hypotensive medications
Preservative-free brimonidine was among the first PG ana-
logues available in a BAK-free preparation as brimonidine 
purite since 1996. Brimonidine purite is preserved with a 
SOC known as Purite®. In this formulation, the concentra-
tion of brimonidine was lowered from 0.2% to 0.15%. In 
randomized, double-masked trial, either brimonidine 0.2% 
or brimonidine purite was administered to 407 patients twice 
a day for 3 months. Both drugs were comparable in efficacy. 
The most common adverse event was hyperemia, which was 
reported less among participants who used brimonidine purite 
compared with brimonidine 0.2%. The difference was not 
statistically significant.79 Another randomized, controlled, 
double-blind study performed for 1 year, however, did report 
that brimonidine purite was significantly more comfortable 
and safer for patients’ use.80 Another medication available in 
a preservative-free formulation is timolol. One study found 
that the basal tear turnover, evaluated using computerized 
objective fluorophotometry, was, decreased by 30% in sub-
jects using preserved timolol and increased approximately by 
30% after subjects switched from preserved timolol to pre-
servative-free timolol after 2 weeks compared with healthy 
controls. Participant inclusion criteria required subjects who 
used timolol plus BAK for at least 1 month before the trial 
began. TBUT values were decreased for both preserved and 
unpreserved timolol-treated eyes as compared with healthy 
controls.73 In another study where all patients were treated 
for at least 1 year with preserved β-blockers, unpreserved 
timolol, or 2 or more preserved medications, inflammatory 
markers in impression cytology samples exhibited a higher 
concentration of all markers, especially human leukocyte Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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antigen. Immunoinflammatory marker interleukin-8 was 
more elevated among those using preserved medications 
rather than unpreserved timolol.81 There are several stud-
ies that also report similar findings in regards to preserved 
medications causing detrimental effects to the ocular surface 
compared with preservative-free medications.82,83
Preservative-free PG analogues
Recently, an effort has been made to create preservative-free 
solutions for antiglaucoma medications. PG analogues have 
come into favor among ophthalmologists as they are the most 
effective drugs for the treatment of ocular hypertension84 and 
maintain fewer systemic side effects compared with older 
β-blockers, miotics, and adrenergic agonists.85 Generally, 
bimatoprost, latanoprost, and travoprost are the PG ana-
logues available. Studies comparing the efficacy of these 
drugs show that these 3 PG analogues along with timolol 
are the most effective drugs at lowering IOP compared 
with most other classes of ocular hypotensives being used 
today.12 Reports of side effect profiles of the 3 PG analogues 
available differ; however, latanoprost is usually associated 
with less hyperemia.86,87 Currently, travoprost is the only 
preservative-free PG analogue available. In the following 
discussion, BAK-free travoprost is reviewed.
Travoprost BAK-free
Travoprost BAK-free solution (Travatan Z®; Alcon Labora-
tories, Inc, Fort Worth, Texas, USA) is the first PG analogue 
without BAK preservative made for commercial use. It is 
preserved with sofZia, which, as previously described, is 
an ionic buffered system. The efficacy of travoprost with 
and without BAK is demonstrated to be significantly equal 
in regards to the ability to lower IOP among 661 patients 
diagnosed with open-angle glaucoma or ocular hypertension 
over a period of 3 months, with 95% confidence intervals 
within ±0.8 mm Hg. Within this study, treatment-related 
ocular hyperemia was reported 9.0% of the time among those 
using travoprost preserved with 0.004% BAK and 6.4% of the 
time among those using BAK-free travoprost, but these data 
were not statistically significant. Observable change from 
baseline in regards to change in visual acuity, ocular signs 
of inflammation, dilated fundus examinations, and visual 
fields was not worrisome in either group, indicating that the 
BAK-preserved and BAK-free formulation have tolerable 
safety assessments. This study did not evaluate patients’ 
comfort. Attrition rates due to treatment-related side effects 
were recorded to be 1.5% in travoprost BAK-free and 1.2% 
in travoprost 0.004% BAK.88
A recently reported double-blind, randomized, controlled 
trial compared the evaluation of patients’ comfort after a 
single dose of BAK-free travoprost 0.004% in 1 eye and 
latanoprost 0.005% in the other eye. Patients underwent a 
3-day washout period during which patients did not use any 
glaucoma medications to allow ocular surface epithelial 
turnover. One drop of medicine was administered in one eye. 
Comfort was measured by a baseline visual analogue scale 
(VAS) given at every 5 seconds for first minute and then at 
2, 5, 10, 15, 20, and 30 minutes. After this was completed, 
1 drop of the other medicine was administered in the oppo-
site eye and the VAS was completed as with the first eye. 
Results from the completed VAS demonstrated no difference 
in comfort level after 5 seconds of eye-drop administration, 
and the average comfort ratings were comparable with con-
trolled untreated subjects. Mean levels of peak discomfort 
were also similar, but the average time needed to return to 
baseline levels of comfort was higher for those using latano-
prost than for those using BAK-free travoprost; however, 
this was not significant. A comfort survey completed by the 
study subjects revealed no difference between the 2 drugs 
in regards to burning, stinging, or foreign body sensation. 
Participants favored latanoprost 31% of the time and BAK-
free travoprost 33% of the time, while they reported no 
preference 35% of the time. Though this study importantly 
demonstrates no significant differences in comfort between 
BAK-free travoprost and latanoprost preserved with BAK, the 
data collected were after only 1 dose. If the medications were 
given chronically, a more clinically meaningful conclusion 
regarding adverse effects of BAK-preserved and BAK-free 
medications in the anterior segment of the eye could have 
been made.89 In vitro studies compared the differing effects 
of 30-minute exposure to travoprost BAK-free with preserved 
travoprost, commercially available latanoprost, phosphate 
buffer saline (PBS) control, and BAK alone at concentrations 
found in commercial formulations on the Wong-Kilbourne 
conjunctiva-derived cell line. The outcome measurements 
used included assays for cell viability, cellular proliferation, 
membrane integrity, and cytotoxicity. All measures were 
elevated in cells exposed to preserved latanoprost and BAK 
alone. There was no difference in cells exposed to PBS con-
trol and BAK-free travoprost.90
Another group used human corneal epithelial cell cul-
ture systems to demonstrate the effect of preserved latano-
prost compared with BAK preservative-free travoprost. 
For   controls, this group used lubricant eye drops, 70% 
methanol, and 0.3% gentamicin sulfate; the latter 2 are known 
to be cytotoxic. Measurements were made using fluorescent Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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molecular probes, one of which reacts with esterase in live 
cells and one of which crosses through compromised cell 
membranes. The cells were incubated in undiluted medica-
tions for 25 minutes and were then evaluated. Results were 
reported as percentages of the live controls. Of the cells 
exposed to BAK-free travoprost, approximately 56.2% 
were viable, whereas in those exposed to latanoprost only 
approximately 5.1% were viable. The percentage of cells 
viable after latanoprost exposure was not very different than 
those exposed to the dead controls; this was, however, not 
statistically significant.91
In vitro studies may not accurately reflect the effect of 
medication on the ocular surface as the physiologic con-
junctival environment cannot be re-created in the laboratory 
setting. One criticism of using in vitro studies, particularly 
of the human corneal epithelial cell culture system – mono-
layer, is that results from these cells do not accurately 
reflect the cornea’s ability to tolerate effects of preser-
vatives. In comparison, stratified cell layers expressing 
corneal keratin are shown to provide an effective substrate 
on which to perform in vitro studies with more realistic 
results.92   Khoh-Reiter and Jessen used the 3-dimensional 
corneal epithelial cultures, which showed that this system 
expressed 3 of the tested corneal epithelial markers more 
than in the monolayer cell system; they compared the effect 
of latanoprost preserved with 0.02% BAK, olopatadine 
(0.01% BAK), and   BAK-free travoprost after exposure for 
10 and 25 minutes. Concomitantly, this research group also 
instilled commercially available latanoprost or its vehicle 
containing 0.02% BAK in monkey eyes and performed 
pachymetry at regular intervals for 1 year. Corneal thick-
ness is suggestive of ocular inflammation secondary to 
edema.93 Among cells exposed to test solutions, only those 
exposed to positive controls demonstrated decreased cell 
viability after 10 minutes of exposure. After 25 minutes, cell 
viability decreased significantly in cell cultures exposed to 
latanoprost. The authors of this study noted that there was 
no significant difference among the decreases in viability 
after 25 minutes between latanoprost and olopatadine 
when each was compared with BAK-free travoprost. In the 
pachymetry arm, study monkey corneas that were exposed 
to a twice-daily 30 µL dosing of latanoprost in 1 eye and 
vehicle with 0.02% BAK in the other were compared with 
control monkey corneas, where vehicle with 0.02% BAK 
was used in 1 eye and the other was not treated. Results 
did not show histological signs of ocular irritation or a sig-
nificant difference in corneal   thickness between the study 
group and the controls.94
Though in vitro studies have very clear limitations, they 
do provide a description of the effects of these drugs on 
  certain cell types relative to the other drugs being evaluated. It 
is, thus, very clear that travoprost BAK-free is less or at least 
equally detrimental to these conjunctival cells in relation to 
commercially available latanoprost. Perhaps the physiologic 
ocular surface attenuates or exacerbates this relationship.
An in vivo model used to study these medications is the 
animal model. Often, rabbits’ eyes are used. Whitson et al95 
evaluated the effects of travoprost without BAK compared 
with latanoprost after administering a 3-minute bath in 1 eye 
of New Zealand rabbits and then 1 drop/min for 3 minutes 
in the other eye. In vivo confocal microscopy of the corneas 
immediately after exposure revealed no changes in cell 
shape or structure in eyes exposed to travoprost BAK-free 
as compared with smaller, brighter cells with irregular bor-
ders noted on the corneas of eyes exposed to commercially 
prepared (preserved with BAK) latanoprost. Differences 
were statistically significant.95 This study is helpful in that 
it uses a live animal model rather than in vitro testing, and 
this dosing regimen model allows investigators to quickly 
establish whether an immediate toxic effect is elicited. 
One may argue that the prolonged exposure time does not 
simulate a normally prescribed dosing regimen for patients. 
Much of the studies of Travatan Z that are available utilize 
cells, tissue, or in vivo exposure to test solutions for greater 
amounts of time than human eyes. In clinical settings, drops 
reside on the ocular surface for an average of 2.9 seconds. 
Many investigators inoculate substrate tissue for many more 
  seconds to even minutes in order to demonstrate possible 
toxic effects quickly. Thus, many effects that these   studies 
describe may not be a true extrapolation to the effects on 
patients’ eyes. However, BAK remains on the ocular sur-
face as it is a detergent, which incorporates itself into cell 
  membranes.96 There is, thus, a reason to believe that the 
exposure time in laboratory settings could actually be shorter 
than in clinical settings. One study that dosed rabbits’ eyes in 
a once-  a-day fashion as in the   clinical setting also reported 
similar   findings. Investigators treated the rabbits’ eyes once 
per day for 30 days and then killed the animals. Conjunctival 
tissue was plated, and masked evaluators counted lympho-
cytes to measure the degree of inflammation. Corneas were 
also viewed under an electron microscope, and masked phy-
sicians graded the quality in regards to microvilli changes. 
Eyes treated with   travoprost and artificial tears demonstrated 
  significantly lower inflammatory cell infiltration compared 
with   latanoprost with BAK. There was no significant 
  difference in eyes treated with travoprost vs artificial tears. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
885
Efficacy and patient tolerability of travoprost BAK-free
In addition, eyes that were subjected to latanoprost preserved 
with BAK demonstrated a fibroblast infiltration, which was 
not seen in eyes treated with travoprost. Corneal changes 
as measured by qualitative grading of microvilli were also 
significantly different between travoprost and latanoprost. 
Again, differences seen between travoprost and artificial 
tears were not significant.97 These results are important as 
they exhibit changes on the ocular surface after eyes were 
exposed to therapeutic doses for an extended period of time. 
Moreover, the results are consistent with in vitro findings 
that exhibit the detrimental effects of BAK, but at prolonged 
exposure and incubation times.
As with in vitro study models, animal models also have 
their limitations that are notable. Several studies performed 
on rabbits’ eyes are scrutinized for using rabbits as models 
for measuring toxicity. One study indicates that rabbits’ 
eyes are more prone to corneal irritation98 and are suscep-
tible to irritant effects for longer periods of time.99 Though 
there are no perfect animal models, these types of studies 
serve the purpose to evaluate medications in a physiological 
environment.
A randomized, controlled, double-blind study enrolled 
109 human subjects who had glaucoma or ocular hyperten-
sion and who underwent a washout period specific for their 
previous medications. They were then given either travoprost 
or Travatan Z for 2 weeks, which is an established time 
period for travoprost to optimize IOP.100 Participants’ IOPs 
were measured on the 14th and 15th day at 8 am and 8 pm, 
and at 36, 48, and 60 hours post last dose. Patient-reported 
and physician-observed adverse events were also recorded. 
The 2 medications cause similar and statistically significant 
lowering of IOP at all times measured, implying that BAK 
does not hinder ocular hypotensive effects and that travoprost 
preserved with sofZia is efficacious. The adverse-event 
profile was also similar, Travatan Z being associated with 3 
reports of either dry eye or hyperemia and travoprost with 
BAK being associated with 4 reports.101
It is well known to practicing ophthalmologists that 
  certain individuals react to BAK-preserved formulations 
with severe hyperemia and ocular surface inflammation, 
whereas others do not demonstrate a response. It is, thus, 
important to recognize that “BAK-sensitive” individuals are 
important to evaluate when considering the effects of BAK 
preserved vs BAK-free ophthalmic solutions so that clinicians 
can   optimize treatments for their patients. One study enrolled 
patients who were found to have a decreased tolerability to 
traditionally preserved PG analogues. All patients were using 
either latanoprost or bimatoprost for at least 1 week and 
then were asked to discontinue and start using Travatan Z 
once each morning for 12 weeks. Outcome measurements 
were conducted using OSD index (OSDI) score comparison, 
Goldmann applanation tonometry, conjunctival hyperemia 
grading, Snellen visual acuity, and slit lamp biomicroscopy. 
OSDI scores were an average of 8.7 for travoprost BAK-free, 
12.0 for latanoprost, and 13.2 for bimatoprost. Interestingly, 
patients who, on visit 1, demonstrated more severe reactions 
to their original medications showed a greater reduction in 
OSDI scores than those who demonstrated more mild symp-
toms initially, though all patients reported some reduction in 
OSDI score after using travoprost BAK-free. Remarkably, 
of the patients who reported initial severe symptoms, 25% 
reported “normal” after switching to the preservative-free 
formulation. IOP decreased in those who switched from 
latanoprost but not for those who switched from bimatoprost. 
Hyperemia and visual acuity were significantly reduced and 
improved, respectively, with the use of travoprost BAK-free. 
Adverse events were still reported with the use of travoprost, 
including conjunctival hyperemia in 6% and a small change 
in visual acuity in 4% of participants. Among the participants, 
72% reported that they preferred preservative-free travoprost 
to their previous medication.102 Though these results show 
an impressive improvement after switching to BAK-free PG 
analogue formulations, it is important to note that this trial 
did not have a control group and the participants were, thus, 
not masked. As every participant’s symptoms improved with 
BAK-free preparations, a masked, double-blind, randomized, 
controlled trial evaluating these parameters is warranted.
Conclusion
Primary open-angle glaucoma is expected to be a significant 
contributing factor to the increasing rates of irreversible 
blindness. As the prevalence of this disease is expected to 
increase in the upcoming years, it is important that medi-
cal therapy be optimized to prevent the progression of the 
pathologic process and maximize the safety profiles to ensure 
patients’ comfort. Medical treatment is effective if admin-
istered properly, but comfort concerns often cause patients 
to neglect taking their medications. Reduced comfort and 
consequent reduced adherence to dosing regimens are widely 
attributed to the preservative used in most glaucoma medi-
cations. BAK is repeatedly implicated in the ocular surface 
adverse events that are reported. As PG analogues cause 
minimal systemic side effects, they are preferred by patients 
and physicians. The main side effect profile includes ocular 
hyperemia and inflammation. In light of the well-documented 
association of BAK and OSD, BAK-free PG formulations Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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should be expected to demonstrate an even smaller side effect 
profile. Given the far-reaching effects of ocular inflammation 
in regards to adherence and failure of filtration surgery, this 
advancement appears to be much needed.
Several studies, as delineated here, illustrate that the new 
BAK-free PG analogue, Travatan Z, demonstrates similar 
efficacy, even up to 60 hours after the last dose once the 
drug is at therapeutic levels, and reduced amounts of   cellular 
toxicity. Upon reviewing the literature, it is evident that 
more randomized, controlled, double-masked studies are 
needed to evaluate the expected improved safety profile for 
this medication. In the randomized, controlled, double-blind 
study completed by Gross et al,101 patients used the medica-
tions for only 2 weeks. Perhaps a longer time period will 
illicit a difference in patients’ comfort between travoprost 
preserved with BAK and Travatan Z. In the randomized 
controlled trial by Henry et al,102 one of the inclusion criteria 
was that patients were having ocular irritation while using 
BAK-preserved medications before the trial initiation. This 
is important to note as not all patients are as sensitive to the 
adverse reaction as described with BAK use. It is, therefore, 
of interest to evaluate Travatan Z in those patients who are 
inclined to react unfavorably. Having a preservative-free 
PG analogue as an option for glaucoma treatment will allow 
for more personalized and effective patient care. If a drug 
regimen that does not conflict with patients’ well-being or 
decrease their quality of life can be established, the treatment 
of glaucoma will be significantly enhanced. Further investi-
gation of Travatan Z may yield promising results.
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